MedPath
HSA Approval

Lormalzi Concentrate for Solution for Infusion 350mg/20mL

SIN17201P

Lormalzi Concentrate for Solution for Infusion 350mg/20mL

Lormalzi Concentrate for Solution for Infusion 350mg/20mL

March 11, 2025

DKSH SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantDKSH SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

N06DX05

Manufacturer Information

DKSH SINGAPORE PTE. LTD.

Lilly France

Active Ingredients

Donanemab

350mg/20mL

Donanemab

Documents

Package Inserts

LORMALZI PI.pdf

Approved: March 11, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Lormalzi Concentrate for Solution for Infusion 350mg/20mL - HSA Approval | MedPath